The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose
Osteoporosis International · 2025
DOI: 10.1007/s00198-025-07672-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoporosis International, 2025. Verfasst von Natalia Konstantelos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. natalia.konstantelos@gmail.com. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Density Conservation Agents, Osteoporosis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
We examined characteristics of patients in Ontario, Canada, initiating publicly funded zoledronic acid for osteoporosis from 2006 to 2021. Most patients had prior osteoporosis treatments, with those previously using oral bisphosphonates more likely to receive a second dose. Understanding treatment decisions and patient beliefs is key for future research. PURPOSE: Zoledronic acid is a once-yearly intravenous bisphosphonate and is considered a second-line osteoporosis therapy in Ontario, Canada. This regimen was approved using evidence from clinical trials of treatment-naïve patients. However, many patients initiating zoledronic acid have used other osteoporosis medications prior, which may influence the frequency of dosing. We describe the characteristics of patients initiating zoledronic acid and identify if previous osteoporosis pharmacotherapy impacts the receipt of a second dose. METHODS: Healthcare administrative data in Ontario were used to identify older patients initiating publicly funded zoledronic acid from 10/2006 to 10/2021 and followed until 10/2022. Patients were categorized based on 5-year osteoporosis treatment look back history in mutually exclusive groups: (1) no history, (2) denosumab, (3) oral bisphosphonates, and (4) other osteoporosis medications. Cox proportional hazards models were used to compare receipt of a second zoledronic acid infusion between patients in treatment history groups. RESULTS: We identified 3308 patients initiating zoledronic acid; median age = 77, 81% female, 31% received a second infusion of zoledronic acid. Half (49%) had a history of oral bisphosphonates, 37% no history, 11% denosumab, and 3% other medications. Overall, patients having history of oral bisphosphonates were 1.5 times more likely to receive a second dose relative to no history (HR, 95%CI: 1.50 [1.31-1.71]). CONCLUSION: In contrast to patients in pivotal trials, most patients receiving zoledronic acid had prior osteoporosis pharmacotherapy. Patients with prior oral bisphosphonate use had higher rates of receiving a second dose. Better understanding of treatment decisions and patient beliefs around receiving a second infusion of zoledronic acid should be further investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. natalia.konstantelos@gmail.com.
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
- Women's College Hospital, Toronto, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
- Department of Medicine, University Health Network, University of Toronto, Toronto, Canada.
- ETH Zurich, Zurich, Switzerland.
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Konstantelos, N., Kim, S., Cheung, A. M., Burden, A. M., Grootendorst, P., & Cadarette, S. M. (2025). The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose. Osteoporosis International. https://doi.org/10.1007/s00198-025-07672-1
Vancouver
Konstantelos N, Kim S, Cheung AM, Burden AM, Grootendorst P, Cadarette SM. The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose. Osteoporosis International. 2025. doi:10.1007/s00198-025-07672-1
BibTeX
@article{Konstantelos2025,
author = {Konstantelos, Natalia and Kim, Sandra and Cheung, Angela M and Burden, Andrea M and Grootendorst, Paul and Cadarette, Suzanne M},
title = {The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose},
journal = {Osteoporosis International},
year = {2025},
doi = {10.1007/s00198-025-07672-1}
}
EUVIMED